基因治療的印度市場評估:各類型，媒介，遺傳基因疫苗接種方法，各用途，各給藥途徑，各終端用戶，各地區，機會，預測(2018年度～2032年度)

印度基因治療市場規模預計將從 2025 財年的 6,925 萬美元增至 2032 財年的 4.9259 億美元，2025 財年至 2032 財年的複合年增長率為 32.35%。市場成長得益於對生物技術新創公司的投資增加、監管部門批准和專利授權數量的增加、遺傳疾病威脅的增加以及產學界合作的加強。基因療法的日益普及可歸因於它能夠為以前被認為無法治癒的多種疾病提供治療。

日本加大力度普及各種基因療法也對市場擴張產生了正面影響。 2024 年 2 月，首次針對 A 型血友病基因治療的人體臨床試驗在韋洛爾基督教醫學院 (CMC) 進行。此臨床試驗採用了新技術在患者的造血幹細胞中表達 FVIII 轉基因。生物技術局預計該載體將進行進一步的臨床試驗，並很快在印度生產。

此外，該國的研究活動預計將增加各種基因療法的可用性。 2024 年 6 月，聯邦部落事務部官員宣布，該國即將開發出針對鐮狀細胞疾病的有效基因療法，鐮狀細胞疾病是一種在預定部落中非常流行的遺傳性血液疾病。根據《柳葉刀》發表的一篇論文，印度的血紅蛋白 S 變異嬰兒出生率排名第三。它還具有世界上頻率最高的血紅蛋白 S 等位基因。因此，越來越需要有效的療法來治療和控制這種疾病。這些進展和政府行動預計將使鐮狀細胞疾病患者能夠接受有效的治療並對抗這種疾病。

本報告提供印度的基因治療市場相關調查分析，提供市場規模與預測，市場動態，主要企業的形勢等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 印度的基因治療市場預測(2018年度～2032年度)

• 市場規模的分析與預測
  • 金額
  • 數量
• 市場佔有率的分析與預測
  • 各類型
  • 各媒介
  • 各遺傳基因疫苗接種方法
  • 各用途
  • 各給藥途徑
  • 各終端用戶
  • 各地區
  • 市場佔有率分析:各企業(金額)(主要企業及其他 - 2024年度)
• 市場地圖分析(2024年度)
  • 各類型
  • 各媒介
  • 各遺傳基因疫苗接種方法
  • 各用途
  • 各給藥途徑
  • 各終端用戶
  • 各地區

第5章 供需分析

第6章 進口和出口的分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

• 推動市場要素
• 市場課題

第12章 市場趨勢與發展

第13章 法規結構和革新

• 臨床試驗
• 法規當局的認證

第14章 專利形勢

第15章 案例研究

第16章 競爭情形

• 主要市場領導者的競爭矩陣
• 主要企業的SWOT分析
• 市場主要企業的形勢
  • ImmunoACT
  • APAC Biotech Pvt. Ltd.
  • Stempeutics Research Pvt Ltd.
  • SEWON E&C CO., LTD.

第17章 策略性推薦

第18章 本公司相關資料，免責聲明

India gene therapy market is projected to witness a CAGR of 32.35% during the forecast period FY2025-FY2032, growing from USD 69.25 million in FY2025 to USD 492.59 million in FY2032. The growth of the market is supported by rising investments towards biotech startups, increasing approvals and provision of patents by regulatory bodies, growing threat of genetic diseases, and increasing industry-academia collaborations. The growing popularity of gene therapy can be attributed to the provision of treatment for a broad range of previously deemed incurable diseases.

The increasing efforts to propel the availability of different gene therapies in the country also positively influence the market's expansion. In February 2024, the first human clinical trials for gene therapy for hemophilia A were conducted at Christian Medical College (CMC) Vellore. The trials included deploying a new technology for expressing FVIII transgene in the patient's hematopoietic stem cell. The Department of Biotechnology hopes the vector will proceed with further clinical trials and soon be manufactured in India.

Additionally, the country's research efforts are also expected to augment the availability of different gene therapies. In June 2024, officials of the Union Tribal Affairs Ministry announced that the country is getting closer to developing an effective gene therapy for sickle cell disease, a highly prevalent genetic blood disorder among the scheduled tribes. According to an article published in the Lancet, India has the third-highest birth rate for babies with hemoglobin S mutation. It is among the highest hemoglobin S allele frequencies across the globe. Thus, the country's need for effective therapies to treat and manage the condition is increasing. Such developments and government efforts are expected to allow the patient population living with sickle cell disease to receive effective therapeutic solutions and combat the disease.

Rising Number of Approvals Boost the Market

The rise in approvals for gene therapies from different regulatory bodies and the provision of patents are propelling the Indian gene therapy market size. In January 2024, Kolon Life Science, Inc. announced that their patent KLS-3021, recombinant vaccinia virus for anti-cancer gene therapy, and KLS-2031, treating and alleviating pain for neuropathic pain gene therapy, won registration in India. Such approvals can be attributed to the successful outcomes of different gene therapies in clinical trials and their promise of delivering more effective and targeted treatments, especially for patients with chronic and rare diseases for which effective treatment options remain unavailable. The innovative approach aids in treating various diseases by delivering functional genes in cells to replace defective or missing genes.

Additionally, due to the vast potential of gene therapy to provide a cure for a wide range of diseases and disorders, research activities to assess their functioning and evaluate their safety and efficacy are increasing, ensuring the availability of new therapies and supporting the India gene therapy market growth.

Increasing Collaborations Support Market Expansion

The increasing collaborations between leading biotech companies and research institutions in the country are expected to bolster the India gene therapy market. In July 2024, Miltenyi Biotec B.V. & Co. KG and Translational Health Science and Technology Institute (THSTI) announced a partnership for exploring gene and cell therapies for cancer treatment. Through collaboration, both organizations aim to address the increasing requirements for innovative cancer therapies and sickle cell disease. Such partnerships are expected to bolster the development and availability of novel therapeutic solutions to meet the unmet demands of patients in arenas where conventional treatment solutions have fallen short.

Due to the broader economic and societal impact of different chronic diseases that are devoid of affordable and effective treatment solutions, research activities towards gene therapies are increasing to address the underlying cause of chronic disease and halt its progression.

Increasing Investments Bolster Market Growth

The rising investments in the development and availability of gene therapies in India are expected to provide lucrative growth opportunities to the market. These therapies can potentially treat inherited disorders and often require a course for a short period or a single dose administration and address the cause of the disease, often providing a cure. Thus, various biotech startups are increasingly focusing on developing gene therapies, including CAR-T, and are receiving more investments from major healthcare and pharmaceutical companies, augmenting the growth of the India gene therapy market. The enhanced funding opportunities and strategic partnerships allow biotech startups to focus on strengthening their in-house research and development capabilities for potential gene therapies. The potential gene therapies and their affordability for patients in India are expected to significantly impact the treatment of previously incurable diseases, including lymphoma and blood cancer, among others.

Oncological Diseases Account for Major Market Share

The growing threat of cancer in the country is propelling the India gene therapy market demand. According to estimates from the National Centre for Disease Informatics and Research (NCDIR), the estimated number of new cancer cases in the country in 2022 was 1,461,427. About one in nine individuals in the country are expected to receive a diagnosis of cancer during their lifetime. This increase is augmenting the requirement for effective treatment alternatives for cancer and bolstering investments toward developing gene therapies that aid in combating oncological diseases. Gene therapy prevents cancer growth by controlling genetic mutations or altered genes. This approach is known as somatic gene therapy and uses the cells and genes of the patients. It does not impact the germ-line cells in the reproductive system, ensuring that no genetic alterations are passed on to the next generation.

Future Market Scenario (FY2025-FY2032F)

As per the India gene therapy market analysis, the market is expected to witness significant growth in the coming years due to the increasing investments in the development of gene therapies and increasing industry-academia collaborations.

The escalating cases of chronic diseases are driving the need for effective therapeutic solutions in India, creating a pressing demand for gene therapy. The estimates and projections from the National Cancer Registry Program further underline this urgency, with the incidence of cancer cases expected to surge by 12.8% in 2025 compared to 2020.

Streamlining of regulatory processes is expected to encourage industry and investigators to initiate more clinical trials for gene therapies in the country without sacrificing rigor. Additionally, the increasing awareness about the current developments in gene therapies is expected to bridge the information gap between government-sponsored organizations, patients, scientists, and clinicians and ensure the availability of effective treatments for patients with genetic disorders.

Key Players Landscape and Outlook

The increasing efforts of the market players to launch affordable and accessible gene therapies in the country in collaboration with leading research and educational institutions are bolstering the growth of the Indian gene therapy market. In April 2024, the first home-grown gene therapy was launched in India, and it is a major breakthrough in aiding the country in battling cancer. The country's first CAR-T cell therapy was developed with a collaboration between ImmunoACT, the Indian Institute of Technology, Bombay, and Tata Memorial Hospital and is expected to inspire similar industry-academia partnerships. Such collaborations are also expected to boost the availability and accessibility of different gene therapies in India and allow the country to battle prevalent diseases that lack effective treatment solutions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Gene Therapy Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Gene Augmentation
    • 4.2.1.2. Gene Silencing
    • 4.2.1.3. Others
  • 4.2.2. By Vector
    • 4.2.2.1. Viral Vectors
    • 4.2.2.2. Non-Viral Vectors
  • 4.2.3. By Gene Delivery Method
    • 4.2.3.1. In vivo
    • 4.2.3.2. Ex vivo
  • 4.2.4. By Application
    • 4.2.4.1. Oncological Diseases
    • 4.2.4.2. Genetic Diseases
    • 4.2.4.3. Cardiovascular Diseases
    • 4.2.4.4. Neuromuscular Diseases
    • 4.2.4.5. Hematological Diseases
    • 4.2.4.6. Infectious Diseases
    • 4.2.4.7. Others
  • 4.2.5. By Route of Administration
    • 4.2.5.1. Intravenous
    • 4.2.5.2. Others
  • 4.2.6. By End-user
    • 4.2.6.1. Hospitals
    • 4.2.6.2. Cancer and Research Institutes
    • 4.2.6.3. Clinics
    • 4.2.6.4. Others
  • 4.2.7. By Region
    • 4.2.7.1. North
    • 4.2.7.2. East
    • 4.2.7.3. West and Central
    • 4.2.7.4. South
  • 4.2.8. By Company Market Share Analysis (Top Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Type
  • 4.3.2. By Vector
  • 4.3.3. By Gene Delivery Method
  • 4.3.4. By Application
  • 4.3.5. By Route of Administration
  • 4.3.6. By End-user
  • 4.3.7. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top Market Leaders
• 16.2. SWOT Analysis for Top Players
• 16.3. Key Players Landscape for Top Market Players
  • 16.3.1. ImmunoACT
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. APAC Biotech Pvt. Ltd.
  • 16.3.3. Stempeutics Research Pvt Ltd.
  • 16.3.4. SEWON E&C CO., LTD.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Gene Therapy Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. India Gene Therapy Market, By Volume, In Thousand Therapies, FY2018-FY2032F
• Figure 3. India Gene Therapy Market Share (%), By Type, FY2018-FY2032F
• Figure 4. India Gene Therapy Market Share (%), By Vector, FY2018-FY2032F
• Figure 5. India Gene Therapy Market Share (%), By Gene Delivery Method, FY2018-FY2032F
• Figure 6. India Gene Therapy Market Share (%), By Application, FY2018-FY2032F
• Figure 7. India Gene Therapy Market Share (%), By Route of Administration, FY2018-FY2032F
• Figure 8. India Gene Therapy Market Share (%), By End-user, FY2018-FY2032F
• Figure 9. India Gene Therapy Market Share (%), By Region, FY2018-FY2032F
• Figure 10. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By Vector Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 12. By Gene Delivery Method Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 13. By Application Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 14. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 15. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 16. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024